Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

NCT02573896 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma

Interventions

DRUG: Dinutuximab
BIOLOGICAL: NK Cells
DRUG: Lenalidomide

Sponsor

New Approaches to Neuroblastoma Therapy Consortium

Collaborators

[object Object]
[object Object]